WHO_HQ-STB_TME-Public-TBCountryProfile
2
Indonesia | High TB burden | High HIV burden | High MDR-TB burden | Tuberculosis profile Population 2009 (millions) 230 Estimates of bur den * 200 9 Numb er ( th ou sa nds) Rate (per 100 000 pop) Mortality ( excluding H IV) 6 1 (36 – 95) 2 7 ( 16 – 41 ) Prevalence (incl HIV) 66 0 (280 – 1 100) 2 8 5 (120 – 482) Incidence (incl HIV) 43 0 (350 – 520) 1 8 9 (154 – 228) Incidence ( HIV-positive) 13 (5.5 – 25) 5.8 (2.4 – 11) Case d etection, all forms ( %) 67 (56 – 83) Case notifications 2009 New cases (%)Retreatment cases (%) Smear-positive 169 213 (59) Relapse 3 710 (65) Smear-negative 108 616 ( 38) Treatment after failure 2 2 5 (4) Smear unknown 0 (0) Treatment after default 7 2 3 (13) Extrapulmonary 11 21 5 (4)Other 1 0 3 0 (18) Other Total new 289 044 Total retreatment 5 6 88 Total < 15 years 3 0 66 2 Total new and relapse 292 754 (99% of total) Total cases notified 294 732 Drug regimens Rifampicin used throughout treatment Yes % of patients treated with fixed-dose combinations (FDCs) 89 Paediatric formulations procured Yes Incidence (HIV+TB in orange), notifications (black) (rates per 100 000 population) 1 99 0 1992 19 9 4 199 6 19 9 8 2 00 0 20 02 2004 2006 20 0 8 0 1 0 0 2 0 0 3 0 0 Prevalence (rate per 100 000 population) 19 90 19 92 19 94 19 96 19 98 20 00 20 02 20 04 20 06 20 08 0 2 0 0 4 0 0 6 0 0 8 0 0 Mortality excluding HIV (rate per 100 000 population) 1 99 0 1992 19 9 4 199 6 19 9 8 2 00 0 20 02 2004 2006 20 0 8 0 2 0 4 0 6 0 8 0 Treatment success rate 2008 (%) New smear-positive 91 New smear-negative/extrapulmonary 88 Retreatment 7 2 Treatment success rate (%) 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 0 40 80 New smear + New smear-/extrap Retreatment TB/HIV 2009 TB patients with known HIV status 2 7 82 % of TB patients wi th known HIV status <1 TB patients that are HIV-positive 4 79 % of tested TB pati ents that are HIV-positive 1 7 % HIV-positive TB patients started on CPT % HIV-positive TB patients started on ART 42 HIV-positive people screened for TB 2 8 12 HIV-positive people provided with IPT 0 CPT (orange) and ART (green) for HIV-positive TB patients (blue) 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 0 10 0 2 0 0 30 0 40 0 MDR-TB, Estimates among notified cases * 2008 % of new TB cases with MDR-TB 2.0 (0.50 – 6.9) % of retreatment TB cases with MDR-TB 15 (0.0 – 40) Estimated MDR-TB cases among notified pulmonary TB cases 2009 6 4 0 0 (1 4 00 – 21 000) MDR-TB reported cases 2009 New Retreat- ment Total Cases tested for MDR-TB % of notified tested for MDR-TB Confirmed cases of MDR-TB MDR-TB patients started treatment 2 0 Financing 2 0 10 2 011 Total budget (US$ millions) 7 1 85 Available funding (US$ millions) 45 3 2 % of budget funded 6 3 38 % available funding from domestic sources 3 4 5 7 % avai lable funding from Global Fund 4 9 4 3 NTP Budget (blue) and available funding (green) (US$ millions) 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 0 2 0 4 0 6 0 8 0 Laboratories 200 8 2009 2 010 Smear (per 100 000 popul ation) 2. 2 2 .2 2.2 Culture (per 5 million population) 1. 3 0. 9 0 .9 DST (per 10 million population) 0.9 0. 2 0.3 Second-line DST available In country National Reference Laboratory N o * Ranges represent uncertainty intervals Generated: January 4, 2011 Source: www.who.int/tb/data
-
Upload
ghina-khairunnisa -
Category
Documents
-
view
217 -
download
0
Transcript of WHO_HQ-STB_TME-Public-TBCountryProfile
8/7/2019 WHO_HQ-STB_TME-Public-TBCountryProfile
http://slidepdf.com/reader/full/whohq-stbtme-public-tbcountryprofile 1/1
Indonesia
| High TB burden | High HIV burden | High MDR-TB burden | Tuberculosis profile
Population 2009 (millions) 230
Estimates of burden * 2009 Number (thousands)Rate
(per 100 000 pop)
Mortality (excluding HIV) 61 (36 – 95) 27 (16 – 41)
Prevalence (incl HIV) 660 (280 – 1 100) 285 (120 – 482)
Incidence (incl HIV) 430 (350 –
520) 189 (154 –
228)
Incidence (HIV-positive) 13 (5.5 – 25) 5.8 (2.4 – 11)
Case detection, all forms (%) 67 (56 – 83)
Case notifications 2009
New cases (%) Retreatment cases (%)
Smear-positive 169 213 (59) Relapse 3 710 (65)
Smear-negative 108 616 (38) Treatment after failure 225 (4)
Smear unknown 0 (0) Treatment after default 723 (13)
Extrapulmonary 11 215 (4) Other 1 030 (18)
Other
Total new 289 044 Total retreatment 5 688
Total < 15 years 30 662
Total new and relapse 292 754 (99% of total)
Total cases notified 294 732
Drug regimens
Rifampicin used throughout treatment Yes
% of patients treated with fixed-dose combinations (FDCs) 89
Paediatric formulations procured Yes
Incidence (HIV+TB in orange), notifications (black)
(rates per 100 000 population)
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008
0
100
200
300
Prevalence (rate per 100 000 population)
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008
0200
400
600
800
Mortality excluding HIV(rate per 100 000 population)
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008
020
40
60
80
Treatment success rate 2008 (%)
New smear-positive 91
New smear-negative/extrapulmonary 88
Retreatment 72
Treatment success rate (%)
1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7
0
40
80 New smear +
New smear-/extrap
Retreatment
TB/HIV 2009
TB patients with known HIV status 2 782
% of TB patients with known HIV status <1
TB patients that are HIV-positive 479
% of tested TB patients that are HIV-positive 17% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART 42
HIV-positive people screened for TB 2 812
HIV-positive people provided with IPT 0
CPT (orange) and ART (green) for HIV-positive TB patients (blue)
2003 2004 2005 2006 2007 2008 2009
0100
200
300
400MDR-TB, Estimates among notified cases * 2008
% of new TB cases with MDR-TB 2.0 (0.50 – 6.9)
% of retreatment TB cases with MDR-TB 15 (0.0 – 40)
Estimated MDR-TB cases among notified
pulmonary TB cases 20096 400 (1 400 – 21 000)
MDR-TB reported cases 2009 NewRetreat-
ment Total
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment 20
Financing 2010 2011
Total budget (US$ millions) 71 85
Available funding (US$ millions) 45 32
% of budget funded 63 38
% available funding from domestic sources 34 57
% available funding from Global Fund 49 43
NTP Budget (blue) and available funding (green) (US$ millions)
2006 2007 2008 2009 2010 2011
020
40
60
80
Laboratories 2008 2009 2010
Smear (per 100 000 population) 2.2 2.2 2.2
Culture (per 5 million population) 1.3 0.9 0.9
DST (per 10 million population) 0.9 0.2 0.3
Second-line DST available In country
National Reference Laboratory No
* Ranges represent uncertainty intervals Generated: January 4, 2011 Source: www.who.int/tb/data
